Incyte (MIL:1INCY) Current Accrued Expense : €681 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Incyte Current Accrued Expense?

Incyte's Current Accrued Expense for the quarter that ended in Mar. 2025 was €681 Mil.

Incyte's quarterly Current Accrued Expense increased from Sep. 2024 (€588 Mil) to Dec. 2024 (€655 Mil) and increased from Dec. 2024 (€655 Mil) to Mar. 2025 (€681 Mil).

Incyte's annual Current Accrued Expense increased from Dec. 2022 (€401 Mil) to Dec. 2023 (€490 Mil) and increased from Dec. 2023 (€490 Mil) to Dec. 2024 (€655 Mil).

Incyte Current Accrued Expense Historical Data

The historical data trend for Incyte's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Current Accrued Expense Chart

Incyte Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

211.60

301.56

401.38

490.00

654.91

Incyte Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															503.09	547.67	587.65	654.91	680.55

Incyte Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Incyte Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Incyte's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (MIL:1INCY) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

INCY:USA INCY:Mexico 0J9P:UK ICY:Germany ICY:Germany

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Headlines

No Headlines